GLENMARK PHARMS LTD
GenericsGLENMARK PHARMS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Dermatology.
GLENMARK PHARMS LTD's Key Drugs
GLENMARK PHARMS LTD's core commercial portfolio centers on EZETIMIBE AND SIMVASTATIN, BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, NORGESTIMATE; ETHINYL ESTRADIOL, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Atherosclerotic Vascular Disease
Glaucoma
Pregnancy prevention
Plaque Psoriasis
Pregnancy prevention
GLENMARK PHARMS LTD's Recent FDA Approvals
GLENMARK PHARMS LTD secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
GLENMARK PHARMS LTD's Therapeutic Areas
GLENMARK PHARMS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GLENMARK PHARMS LTD's Top Competitors
GLENMARK PHARMS LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GLENMARK PHARMS LTD Pipeline Snapshot
Active clinical trials for GLENMARK PHARMS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EZETIMIBE AND SIMVASTATIN leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (19)
Discontinued (1)
Company Info
- First Approval
- 2005-03-07
- Latest
- 2026-07-09
- Applications
- 180